Having sold its corporate self, Tocagen auctions off scientific platform to San Diego biotech

With the dermatitis specialists at Forte Biosciences now inhabiting Tocagen’s corporate skeleton, a small San Diego biotech has won rights to its scientific platform.

Denovo Biopharma, a biotech based in San Diego and backed largely by investors in China, will acquire Tocagen’s retro-viral replicating platform, including their former lead gene therapy for brain cancer.